Versant Venture Management’s Contineum Therapeutics CTNM Stock Holding History

Versant Venture Management’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.89M	Hold	542,628	–	–	5.47%	5
2026 Q1	$7.09M	Hold	542,628	–	–	5.01%	5
2025 Q4	$6.2M	Hold	542,628	–	–	4.11%	5
2025 Q3	$6.38M	Hold	542,628	–	–	3%	6
2025 Q2	$2.15M	Sell	542,628 -375,535	-41%	-$1.63M	2.62%	6
2025 Q1	$6.41M	Hold	918,163	–	–	10.64%	3
2024 Q4	$13.5M	Hold	918,163	–	–	15.51%	3
2024 Q3	$17.6M	Hold	918,163	–	–	27.64%	2
2024 Q2	$16.2M	Buy	+918,163	New	+$14.8M	20.92%	2

Other funds holding CTNM

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Versant Venture Management's CTNM Position: Q2 2026 in Review

Versant Venture Management held its Contineum Therapeutics (CTNM) position steady in Q2 2026 at 542,628 shares worth $8.89M. The position accounts for 5.47% of the portfolio, ranked #5.

Versant Venture Management first reported a position in CTNM in Q2 2024 and has held it in 9 quarters since. The position peaked at $17.6M in Q3 2024. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

Versant Venture Management held 542,628 shares of Contineum Therapeutics worth $8.89M as of Q2 2026.
Versant Venture Management left its Contineum Therapeutics share count unchanged in Q2 2026.
Contineum Therapeutics made up 5.47% of Versant Venture Management's portfolio in Q2 2026, its #5 holding.
Versant Venture Management first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 9 quarters since.
Versant Venture Management's Contineum Therapeutics position peaked at $17.6M in Q3 2024.
102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Versant Venture Management's 13F filing for Q2 2026, filed 12 Aug 2026.